Brevan Howard Capital Management LP Vaxcyte, Inc. Transaction History
Brevan Howard Capital Management LP
- $17 Billion
- Q3 2025
A detailed history of Brevan Howard Capital Management LP transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 67,133 shares of PCVX stock, worth $3.25 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
67,133
Previous 54,995
22.07%
Holding current value
$3.25 Million
Previous $1.79 Million
35.31%
% of portfolio
0.01%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding PCVX
# of Institutions
319Shares Held
133MCall Options Held
408KPut Options Held
116K-
Janus Henderson Group PLC London, X013.1MShares$633 Million0.23% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.3MShares$596 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA12MShares$578 Million7.4% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$480 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD8.32MShares$402 Million0.18% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $2.87B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...